Literature DB >> 16039297

Postprandial increase of plasma apoAV concentrations in Type 2 diabetic patients.

Valérie Pruneta-Deloche1, Gabriel Ponsin, Laure Groisne, Jamila Fruchart-Najib, Michel Lagarde, Philippe Moulin.   

Abstract

Postprandial hypertriglyceridemia is considered as a risk factor for cardiovascular disease in Type 2 diabetes. However, little is known about the underlying mechanisms. Since the recently discovered apolipoprotein (apo) AV was identified as a modulator of triglyceride (TG) metabolism, the aim of the study was to determine the postprandial apoAV profile of Type 2 diabetic patients. We compared data from 11 patients with Type 2 diabetes mellitus to that of 12 non-diabetic normolipidemic subjects following the ingestion of a lipid-rich cream. Postprandial apoAV was elevated in diabetic patients but no correlation was observed either with plasma TG concentration or with the intensity of lipoprotein lipase-dependent lipolysis. These data obtained in human subjects suggest that plasma apoAV concentration does not play an acute or a direct role in the regulation of plasma TG in the postprandial state.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16039297     DOI: 10.1016/j.atherosclerosis.2005.01.034

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  9 in total

1.  Plasma apolipoprotein A5 and triglycerides in type 2 diabetes.

Authors:  G M Dallinga-Thie; A van Tol; H Hattori; L C van Vark-van der Zee; H Jansen; E J G Sijbrands
Journal:  Diabetologia       Date:  2006-04-28       Impact factor: 10.122

2.  Apolipoprotein AV does not contribute to hypertriglyceridaemia or triglyceride lowering by dietary fish oil and rosiglitazone in obese Zucker rats.

Authors:  B Dorfmeister; S Brandlhofer; F G Schaap; M Hermann; C Fürnsinn; B P Hagerty; H Stangl; W Patsch; W Strobl
Journal:  Diabetologia       Date:  2006-03-29       Impact factor: 10.122

Review 3.  Fibrate therapy in patients with metabolic syndrome and diabetes mellitus.

Authors:  Thomas Dayspring; Gregory Pokrywka
Journal:  Curr Atheroscler Rep       Date:  2006-09       Impact factor: 5.113

4.  Association of apolipoprotein A5 concentration with serum insulin and triglyceride levels and coronary artery disease in Korean men.

Authors:  Yae Jung Hyun; Yangsoo Jang; Jey Sook Chae; Ji Young Kim; Jean Kyung Paik; So Yeon Kim; Ju Young Yang; Jose M Ordovas; Young Guk Ko; Jong Ho Lee
Journal:  Atherosclerosis       Date:  2008-12-31       Impact factor: 5.162

Review 5.  The paradox of ApoA5 modulation of triglycerides: evidence from clinical and basic research.

Authors:  Mahdi Garelnabi; Kenton Lor; Jun Jin; Fei Chai; Nalini Santanam
Journal:  Clin Biochem       Date:  2012-09-19       Impact factor: 3.281

6.  Determinants of plasma apolipoprotein A-V and APOA5 gene transcripts in humans.

Authors:  P Hahne; F Krempler; F G Schaap; S M Soyal; H Höffinger; K Miller; H Oberkofler; W Strobl; W Patsch
Journal:  J Intern Med       Date:  2008-06-03       Impact factor: 8.989

Review 7.  Clinical significance of apolipoprotein A5.

Authors:  E Shyong Tai; Jose M Ordovas
Journal:  Curr Opin Lipidol       Date:  2008-08       Impact factor: 4.776

8.  Relationship of Serum Apolipoprotein A-V Levels, Oxidative Stress and Inflammatory Biomarkers with Hypertriglyceridemia in Type 2 Diabetes Mellitus.

Authors:  Devesh Sharma; Seema Garg; Mohit Mehndiratta; S V Madhu; Dinesh Puri
Journal:  Int J Endocrinol Metab       Date:  2017-04-22

9.  Genetic associations with diabetes: meta-analyses of 10 candidate polymorphisms.

Authors:  Linlin Tang; Lingyan Wang; Qi Liao; Qinwen Wang; Leiting Xu; Shizhong Bu; Yi Huang; Cheng Zhang; Huadan Ye; Xuting Xu; Qiong Liu; Meng Ye; Yifeng Mai; Shiwei Duan
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.